Trial NCT00000138

Property	Value
linkedct:brief_title	Herpetic Eye Disease Study (HEDS) I
linkedct:condition	<http://data.linkedct.org/resource/condition/6970>
linkedct:condition	<http://data.linkedct.org/resource/condition/9167>
linkedct:criteria	Eligibility criteria common to the three protocols included age 12 years or older, no active HSV epithelial keratitis, no prior keratoplasty of the involved eye, and not pregnant. Protocol-specific criteria are noted in the description above.
linkedct:description	Herpes simplex keratitis is a leading cause of corneal opacification in the United States, other industrialized countries, and developing nations throughout the world. An estimated 450,000 people in the United States can develop recurrent episodes of the disease and about 46,000 episodes of HSV eye infection every year. Herpetic eye disease is the most common infectious cause of corneal blindness in this country. Despite the availability of antiviral agents that are effective in treating herpes simplex epithelial keratitis, inflammation in the corneal connective tissue and iris that can lead to corneal scarring and visual impairment develops in many patients. Prior to the HEDS-I trials, the role of topical corticosteroids in the management of HSV stromal keratitis was uncertain; some animal and human studies suggested there was a benefit to treatment whereas others suggested harm. The value of adding an oral antiviral agent to treatment with topical corticosteroids and topical antivirals also was unknown. The HEDS-I trials were developed to assess the efficacy of topical corticosteroids and oral acyclovir in treating HSV stromal keratitis and iridocyclitis. HEDS-I consisted of three randomized, placebo-controlled trials. The organizational structure consisted of a data coordinating center and eight clinical centers. All patients received the topical antiviral trifluridine as prophylaxis against recurrences of HSV epithelial ulceration. Patients were evaluated weekly for 10 weeks, every other week through week 16, and again at 6 months. The primary outcome was the time to development of preset criteria for treatment failure during the 16-week period of examination. Protocol-specific descriptions of the three trials follow. Herpes Stromal Keratitis, Not on Steroid Trial (HEDS-SKN): Patients with active HSV stromal keratitis who had not used a topical corticosteroid in the preceding 10 days were randomized to treatment with topical prednisolone phosphate drops or topical placebo drops. A treatment schedule, starting with 8 drops a day of 1 percent prednisolone phosphate for 7 days, was progressively decreased over 10 weeks in such a way that patients received 1 drop per day of 1/8 percent prednisolone for the last 3 weeks of treatment. Placebo drops were given by the same schedule. Herpes Stromal Keratitis, on Steroid Treatment (HEDS-SKS): Patients with active HSV stromal keratitis who already were being treated with a topical corticosteroid were randomized either to oral treatment with 200 mg acyclovir capsules (400 mg five times daily) for 10 weeks or to the identical dose of placebo capsules. Patients also received topical prednisolone phosphate in the dosage schedule described above for the SKN trial. Herpes Simplex Virus Iridocyclitis, Receiving Topical Steroids (HEDS-IRT): Patients with active HSV iridocyclitis were randomized either to oral treatment with 200 mg acyclovir capsules (400 mg five times daily) for 10 weeks or to the identical dose of placebo capsules. Patients also received topical prednisolone phosphate in the dosage schedule described above for the SKN trial.
linkedct:download_date	Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender	Both
linkedct:eligibility_healthy_volunteers	No
linkedct:eligibility_maximum_age	N/A
linkedct:eligibility_minimum_age	12 Years
linkedct:enrollment	0 (xsd:int)
linkedct:firstreceived_date	September 23, 1999
linkedct:id	NCT00000138
rdfs:label	Trial NCT00000138
linkedct:lastchanged_date	September 16, 2009
linkedct:lead_sponsor_agency	<http://data.linkedct.org/resource/agency/2>
linkedct:nct_id	NCT00000138
linkedct:number_of_arms	0 (xsd:int)
linkedct:number_of_groups	0 (xsd:int)
linkedct:org_study_id	NEI-37
linkedct:overall_status	Active, not recruiting
linkedct:oversight	<http://data.linkedct.org/resource/oversight/2918>
foaf:page	<http://clinicaltrials.gov/show/NCT00000138>
linkedct:phase	Phase 3
linkedct:reference	<http://data.linkedct.org/resource/reference/36541>
linkedct:reference	<http://data.linkedct.org/resource/reference/39044>
linkedct:reference	<http://data.linkedct.org/resource/reference/47060>
linkedct:reference	<http://data.linkedct.org/resource/reference/47061>
linkedct:reference	<http://data.linkedct.org/resource/reference/50503>
linkedct:reference	<http://data.linkedct.org/resource/reference/51359>
linkedct:reference	<http://data.linkedct.org/resource/reference/889>
linkedct:reference	<http://data.linkedct.org/resource/reference/890>
linkedct:reference	<http://data.linkedct.org/resource/reference/891>
linkedct:source	National Eye Institute (NEI)
linkedct:start_date	May 1989
linkedct:study_design	Treatment, Randomized, Placebo Control
linkedct:study_type	Interventional
linkedct:summary	To evaluate the efficacy of topical corticosteroids in treating herpes simplex stromal keratitis in conjunction with topical trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex stromal keratitis in patients receiving concomitant topical corticosteroids and trifluridine. To evaluate the efficacy of oral acyclovir in treating herpes simplex iridocyclitis in conjunction with treatment with topical corticosteroids and trifluridine.
rdf:type	linkedct:trials
linkedct:verification_date	September 2009

LinkedCT.org